Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 60 DEGREES PHARMACEUTICALS, INC.SXTP · Entity 8389 | Director | December 31, 2023 | May 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
60 DEGREES PHARMACEUTICALS, INC.
Report date December 31, 2023 · Filed May 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,000 |
Reported balance
After 2024-05-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-16 · Exercise / conversion · Acquired 4,000 · Balance 14,000 F1: This transaction represents the settlement of restricted stock units in shares of common stock on May 16, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,000 |
Reported balance
After 2023-12-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-31 · Grant · Acquired 4,000 · Balance 4,000 F2: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,000 |
Reported balance
After 2024-05-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-16 · Exercise / conversion · Disposed 4,000 · Balance 4,000 F3: 4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents the settlement of restricted stock units in shares of common stock on May 16, 2024.
F2: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.
F3: 4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2024 Filed May 22, 2024 00:20 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-045706 · ownership.xml · derivative · entry 3 FIELD PAUL · CIK 0001976960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: 4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs. F3 · shares: 4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs. F3 · derivative.exercise_date: 4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs. F3 · derivative.expiration_date: 4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs. F3 · derivative.underlying_shares: 4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs. Read SEC document |
| May 16, 2024 Filed May 22, 2024 00:20 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | Exercise / conversionCommon Stock | 4,000 | $0.22 | $892.00 |
DisclosureSEC source: 0001213900-24-045706 · ownership.xml · nonDerivative · entry 1 FIELD PAUL · CIK 0001976960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction represents the settlement of restricted stock units in shares of common stock on May 16, 2024. Read SEC document |
| December 31, 2023 Filed May 22, 2024 00:20 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | GrantRestricted Stock Units · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-045706 · ownership.xml · derivative · entry 2 FIELD PAUL · CIK 0001976960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · security: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023. F2 · shares: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023. F2 · derivative.exercise_date: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023. F2 · derivative.expiration_date: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023. F2 · derivative.underlying_shares: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.